The Medical Advisor

Semaglutide, known by the brand names Ozempic, Wegovy, Rybelsus and others, is the latest weight-loss craze to hit Hollywood and beyond. The prescription drug, which is administered via a weekly injection, is intended to treat Type 2 diabetes, but it’s widely used off-label for weight loss. They all belong to the same medication class — glucagon-like peptide-1 (GLP-1) agonists ( GLP-1 receptor agonists ).  GLP-1 agonists work by triggering insulin release, blocking sugar production in your liver, and making you feel full. But with all of these brands out there, how do you decide which is right for you? Let’s get to know some of the differences between these major GLP-1 agonist drugs. A 2021 study funded by Novo Nordisk, the drug’s maker, found using semaglutide once a week led to a 14.9% reduction in body weight among adults with obesity. There’s been such a rush on the drugs that the U.S. Food and Drug Administration lists both Ozempic and Wegovy a...

Introduction In recent years, GLP-1 receptor agonists have emerged as one of the most important breakthroughs in modern metabolic medicine. Originally developed to treat type 2 diabetes, these medications are now widely used for weight loss, cardiovascular risk reduction, and metabolic disease management . Drugs such as Ozempic, Wegovy, and Mounjaro have rapidly gained global attention for their ability to produce significant and sustained weight loss while improving multiple cardiometabolic risk factors. GLP-1 (glucagon-like peptide-1) is a natural hormone released from the gut after eating. It plays a key role in regulating blood sugar, appetite, and digestion. By mimicking or enhancing this hormone’s activity, GLP-1 drugs help reduce hunger, slow gastric emptying, improve insulin secretion, and support healthier glucose control. Over the past decade, large randomized clinical trials have demonstrated that these medications can lead to 10–20% reductions in body weight , alongside me...

⚠️ IMPORTANT MEDICAL DISCLAIMER: Retatrutide is an investigational drug and is not yet FDA-approved for weight loss or type 2 diabetes. The information below is for educational and news-tracking purposes based on clinical trial data published in 2026. Always consult a healthcare provider for currently available, approved weight-loss treatments. The landscape of medical weight loss is shifting at a breakneck pace. While semaglutide (Wegovy) and tirzepatide (Zepbound) dominated headlines over the last few years, a new powerhouse is poised to redefine obesity treatment: Retatrutide . Developed by Eli Lilly, Retatrutide is a "triple-agonist" peptide targeting three hunger-regulating receptors. With highly anticipated Phase 3 topline data officially published in early 2026, this drug is shaping up to be the most potent weight-loss medication ever developed. Here is your comprehensive, regularly updated hub on Retatrutide’s 2026 trial results, FDA time...

At a glance Some natural alternatives to Ozempic include berberine, which may help manage blood sugar and support weight loss, along with high-protein diets, fiber-rich foods, and drinking water before meals to help control appetite. However, these options are generally not as potent or predictable as prescription medications like Ozempic, so they should not be viewed as direct substitutes for medical therapy. There are natural alternatives to Ozempic like berberine, turmeric and psyllium husk. Ozempic is a popular weight-loss medication that helps curb appetite and induces various metabolic changes linked to improved weight management. However, this injectable medication is costly, and its long-term use may lead to serious health issues, including thyroid cancer, muscle mass loss, and kidney damage. The  2023 report  from the World Obesity Federation estimates that the economic impact of overweight and obesity will surpass $4.3 trillion annually by...